Glecaprevir/Pibrentasvir for Post-traumatic Stress Disorder

Summary

A double-blind randomized placebo-controlled trial to further investigate glecaprevir/pibrentasvir (GLE/PIB), a direct acting antiviral (DAA) that has been associated with posttraumatic stress disorder (PTSD) symptom improvement when prescribed for the treatment of chronic hepatitis C viral infection (HCV).

Timeline

Start

2023-12-18

Primary completion

2025-12-31

Completion

2026-09-30

Drugs

Indications